Physician profile
Haley Hernandez
NPI 1841920840
$7,492.70
in general payments reported to CMS, 2019-2025
22 companies · $2,420 in 2025
The $2,420 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,433 · 2024: $3,640 · 2025: $2,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,487 · Education: $5.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,487.11 |
| Education | $5.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,441.97 | 2024-2025 | Qelbree |
| Abbvie INC. | $1,016.05 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $819.38 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $458.65 | 2023-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $431.34 | 2023-2025 | Auvelity |
| Corium, LLC | $423.45 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $363.51 | 2024 | |
| Alkermes, INC. | $341.57 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $334.17 | 2024-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $285.79 | 2023-2025 | Ingrezza |
| Almatica Pharma LLC | $259.62 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $194.97 | 2023-2024 | Quviviq |
| Lundbeck LLC | $187.03 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $175.24 | 2023-2025 | Spravato, Invega Sustenna |
| Collegium Pharmaceutical, INC. | $162.54 | 2025 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $149.79 | 2024-2025 | Austedo Xr, Austedo Xr |
| Tris Pharma INC | $148.70 | 2023-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $144.84 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $75.91 | 2023-2025 | Trintellix |
| Noven Therapeutics, LLC | $38.33 | 2025 | Xelstrym, Secuado |
| Luye Pharma (USA) LTD. | $26.29 | 2025 | Erzofri Extended-Release |
| Neos Therapeutics, LP | $13.56 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.